PMID: 15222780Jun 30, 2004Paper

Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice

Radiation Research
R E J MitchelS M Carlisle

Abstract

Trp53 heterozygous mice are radiation-sensitive and cancer-prone. Groups of 7-8-week-old female Trp53 heterozygous mice were exposed to 4 Gy of 60Co gamma radiation at high (0.5 Gy/min) or low (0.5 mGy/min) dose rate. Other groups received 10 or 100 mGy at low dose rate 24 h prior to the 4-Gy dose. Tumor frequency and latency were measured over the animals' life span. Exposure to 10 mGy prior to 4 Gy resulted in a small (approximately 5%) but significant life-span regain and increased latency (approximately 9%) for all malignant tumors taken together, but 100 mGy further reduced life span slightly (approximately 7%). Latency responses were tumor type-specific. The prior 10-mGy exposure resulted in a small (approximately 7%) regain in latency for lymphomas but no change in latency for spinal osteosarcomas. Increasing the adapting dose to 100 mGy eliminated the increase in lymphoma latency and further reduced life span (approximately 8%). A 10-mGy dose prior to 4 Gy at low dose rate had no effects. Adapting exposures had no significant effect on tumor frequency. We conclude that a single low dose induced a small protective response in vivo in Trp53+/- mice, reducing the carcinogenic effects of a subsequent large, high-dose-rate e...Continue Reading

References

Mar 1, 1987·Mutation Research·R E Mitchel, D P Morrison
Jan 1, 1994·Current Biology : CB·T JacksR A Weinberg
Nov 1, 1993·Nature Genetics·M HarveyL A Donehower
Sep 23, 1997·International Journal of Radiation Biology·J A DollingR E Mitchel
Nov 30, 1999·International Journal of Radiation Biology·S P CreganR E Mitchel
Jul 11, 2002·Mutation Research·Masao S SasakiTaisei Nomura

❮ Previous
Next ❯

Citations

Dec 1, 2005·Nutrition Research Reviews·David G Lindsay
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·R E J Mitchel
Nov 30, 2006·Radiation and Environmental Biophysics·Soile Tapio, Vesna Jacob
Dec 22, 2007·Radiation and Environmental Biophysics·M P LittleD C Thomas
Dec 6, 2008·Surgical Oncology Clinics of North America·Brandi UptonBenjamin D L Li
Mar 1, 2005·Radiation Research·Ryuji OkazakiToshiyuki Norimura
Jan 26, 2010·Radiation Research·Benjamin J BlythPamela J Sykes
Jun 30, 2010·Dose-response : a Publication of International Hormesis Society·Ronald E J Mitchel
Sep 21, 2016·International Journal of Molecular Sciences·Laura A BannisterDmitry Y Klokov
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·Bobby E Leonard
Apr 1, 2017·Cancer Immunology, Immunotherapy : CII·Marek K JaniakEdward J Calabrese
Apr 4, 2009·Dose-response : a Publication of International Hormesis Society·George R Hoffmann
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·Helmut Schöllnberger, Peter M Eckl
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·R E J Mitchel
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·R E J Mitchel
Jun 29, 2018·International Journal of Radiation Biology·Ilya O VelegzhaninovDmitry Yu Klokov
Dec 26, 2018·International Journal of Radiation Biology·Yi WangDmitry Klokov
Dec 21, 2007·Environmental and Molecular Mutagenesis·Michael KilemadeDouglas Boreham
Jul 26, 2017·Radiation Research·Jennifer A LemonDouglas R Boreham
Jan 26, 2016·Health Physics·Kanokporn Noy Rithidech
Oct 11, 2011·The Journal of Bone and Joint Surgery. American Volume·Dino SamartzisFumiyoshi Kasagi
Apr 9, 2013·American Journal of Clinical Oncology·Russell C LanganItzhak Avital
Jul 26, 2017·Radiation Research·Jennifer A LemonDouglas R Boreham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis